Rockefeller Capital Management’s ADMA Biologics ADMA Stock Holding History

Rockefeller Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30.9K	Sell	3,425 -1,060	-24%	-$16.7K	﹤0.01%	3504
2025 Q4	$81.8K	Buy	4,485 +1,694	+61%	+$28.6K	﹤0.01%	2815
2025 Q3	$40.9K	Buy	+2,791	New	+$47.8K	﹤0.01%	3008
2023 Q1	–	Sell	-1,399	Closed	-$5K	–	1992
2022 Q4	$5K	Hold	1,399	–	–	﹤0.01%	3304
2022 Q3	$3K	Hold	1,399	–	–	﹤0.01%	3454
2022 Q2	$2K	Hold	1,399	–	–	﹤0.01%	3739
2022 Q1	$2K	Hold	1,399	–	–	﹤0.01%	3572
2021 Q4	$1K	Sell	1,399 -490	-26%	-$644	﹤0.01%	3613
2021 Q3	$2K	Hold	1,889	–	–	﹤0.01%	3400
2021 Q2	$3K	Hold	1,889	–	–	﹤0.01%	3135
2021 Q1	$3K	Buy	+1,889	New	+$4.32K	﹤0.01%	3000

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Rockefeller Capital Management's ADMA Position: Q1 2026 in Review

Rockefeller Capital Management reduced its ADMA Biologics (ADMA) stake by 24% in Q1 2026, selling an estimated $16.7K and leaving 3,425 shares worth $30.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3504.

Rockefeller Capital Management first reported a position in ADMA in Q1 2021 and has held it in 11 quarters since. The position peaked at $81.8K in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

Rockefeller Capital Management held 3,425 shares of ADMA Biologics worth $30.9K as of Q1 2026.
Rockefeller Capital Management sold 1,060 ADMA Biologics shares in Q1 2026, an estimated $16.7K.
ADMA Biologics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3504 holding.
Rockefeller Capital Management first reported a position in ADMA Biologics in Q1 2021 and has held it in 11 quarters since.
Rockefeller Capital Management's ADMA Biologics position peaked at $81.8K in Q4 2025.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.